Loading
Latest filing published 17 Jun 2026 for Aprea Therapeutics, Inc..
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Marc Duey is a declared insider of Aprea Therapeutics, Inc., with filings sourced from SEC (Form 4). Between 28 July 2022 and 16 June 2026, the trades on record add up to 11 filings.
In open-market terms, that means 3 purchases worth €143k on one side and 1 sale worth €27k on the other. Netting one side against the other leaves €116k of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 5 share grants.
A typical purchase (the median) is worth €21k. Of 3 purchases, 3 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 3 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -17.5%. Past outcomes like these are no guarantee of what comes next.
The latest filing, published on 17 June 2026, reports a share grant in Aprea Therapeutics, Inc. The most recent open-market purchase was published on 11 December 2025, 319 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations